According to previous studies, the probability of all-grade hypertension is between 15 and 67% during the treatment by using small molecule vascular endothelial growth factor tyrosinase inhibitors (e.g., sunitinib, sorafenib, pazopanib, etc.), and the rate would be higher with the use of inhibitors with higher efficiency (e.g., axitinib) (Brinda et al., 2016). The gene discussed is VEGFA; the disease is hypertensive disorder.